Zimbabwe has declined a significant American health deal valued at 367 million US dollars (272 million pounds) over five years because of Washington's insistence on confidential information.
The decision became public after a internal memorandum dated December was leaked, which showed President Emmerson Mnangagwa deemed the arrangement was "unbalanced".
A government representative later clarified that the United States was demanding access to genetic material for research and profit while refused to guarantee the benefits from any future treatments.
"We must now begin the challenging and unfortunate task of ending our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had donated more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for further negotiations to find a deal suitable to both sides so the country's vital HIV programme can proceed.
Broader Implications
This development comes after a comparable case in Kenya, where a high court halted a similar deal with the US after legal challenges were filed about the security of Kenyans' medical information.
Since returning to the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
USAID had administered assistance for the American government, but Trump argued its expenditure was "wasteful" and his government was pursuing government-to-government agreements to enhance openness and responsibility.
Based on reports, 16 African countries have to date signed similar health pacts, representing over $18.3bn in new funding.
Specifics of the Rejected Agreement
The money for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this collaboration might have yielded extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million currently on antiretroviral therapy through US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"Zimbabwe was being asked to provide its genetic material and health information over an extended period, with no corresponding assurance of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," his statement read.
"Effectively, our nation would provide the raw materials for scientific discovery with no assurance that the resulting innovations would be accessible to our people should a future health crisis arise."
National Interest and International Frameworks
He also said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were disrupting structures previously set up via the global health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme created to deal with future global health emergencies.
"This system is designed to ensure that when a country contributes its samples, the benefits – including medicines and cures – are distributed fairly, not monopolised exclusively by those with the funds to create them."
These objections regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We are open to further dialogue with our US partners on how future co-operation might be arranged in a manner that honours the independence and interests of each country."
Medical Community Response
Medical experts expressed it understood the official position, but suggested that negotiations need to persist considering much of the country's Aids initiatives depended on external financing.
"Where specific concerns exist, including those relating to data governance or implementation frameworks, these can frequently be addressed through detailed discussion and negotiated safeguards," it said.
The halted deal highlights the continuing tensions between accepting crucial foreign assistance and protecting national sovereignty in an ever more data-driven world.